Quick Answer
BIODESIX INC reported Net Income Loss of -$35.27 million for the year ending 2025.
- BIODESIX INC showed an increase of +17.9% in Net Income Loss from 2024 to 2025.
- This data is from BIODESIX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$7.74 million | Q2 2019: -$6.86 million | Q3 2019: -$9.60 million | Q1 2020: -$9.71 million | Q2 2020: -$8.27 million | Q3 2020: -$8.85 million | Q1 2021: -$6.96 million | Q2 2021: -$11.40 million | Q3 2021: -$11.51 million | Q1 2022: -$15.59 million | Q2 2022: -$15.82 million | Q3 2022: -$13.70 million | Q1 2023: -$18.70 million | Q2 2023: -$13.36 million | Q3 2023: -$10.95 million | Q1 2024: -$13.61 million | Q2 2024: -$10.81 million | Q3 2024: -$10.26 million | Q1 2025: -$11.10 million | Q2 2025: -$11.47 million | Q3 2025: -$8.72 million.
- Over the full 7 years of available data (2019 to 2025), BIODESIX INC's Net Income Loss has declined by 14.8%.
- Historical annual values: Fiscal year 2025: -$35.27 million | Fiscal year 2024: -$42.93 million | Fiscal year 2023: -$52.15 million | Fiscal year 2022: -$65.45 million | Fiscal year 2021: -$43.16 million | Fiscal year 2020: -$65.45 million | Fiscal year 2019: -$30.73 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: